NCCN Guidelines (R) Insights Breast Cancer, Version 1.2017 Featured Updates to the NCCN Guidelines

Gradishar, WJ; Anderson, BO; Balassanian, R; Blair, SL; Burstein, HJ; Cyr, A; Elias, AD; Farrar, WB; Forero, A; Giordano, SH; Goetz, MP; Goldstein, LJ; Isakoff, SJ; Lyons, J; Marcom, PK; Mayer, IA; McCormick, B; Moran, MS; O'Regan, RM; Patel, SA; Pie

Gradishar, WJ (reprint author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017; 15 (4): 433

Abstract

These NCCN Guidelines Insights highlight the important updates/changes to the surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in the 1.2017 version of the NCCN Guidelines for Breast Cancer. This report summarizes these updates and discusses the rationale behind them. Updates on new drug approvals, not available at press time, can be found in the most recent version of these guidelines at NCCN.org.

Download PDF


Full Text Link